Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
CLLS Stock Chart & Stats
$3.72
-$0.20(-9.46%)
At close: 4:00 PM EST
$3.72
-$0.20(-9.46%)
Day’s Range― - ―
52-Week Range$1.10 - $5.48
Previous CloseN/A
Volume129.50K
Average Volume (3M)48.77K
Market Cap
$267.40M
Enterprise Value$260.18M
Total Cash (Recent Filing)$52.24M
Total Debt (Recent Filing)$37.58M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Mar 11, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding72,325,455
10 Day Avg. Volume45,655
30 Day Avg. Volume48,775
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.24
Price to Sales (P/S)3.93
P/FCF Ratio8.35
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue3.46
Enterprise Value/Gross Profit3.94
Enterprise Value/Ebitda-42.88
Forecast
1Y Price Target
$6.50Price Target Upside74.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyAnalyst highlights that lasme-cel produced a strong complete response rate in heavily pretreated B‑cell acute lymphoblastic leukemia patients, supporting the therapy's potential for regulatory approval and clinical adoption.
Manufacturing CapabilitiesAnalyst views in‑house manufacturing of the allogeneic CAR T candidate as a competitive advantage that could reduce reliance on external partners and improve supply consistency.
Regulatory ProgressAnalyst expects the planned Biologics License Application in 2028 combined with forthcoming Eti‑cel data updates to clarify commercial prospects and reduce regulatory uncertainty.
Bears Say
Commercial FeasibilityAnalyst cautions that high treatment cost and the need for multiple CAR T infusions followed by stem cell transplants could limit payer coverage and patient access, constraining market uptake.
Liquidity And FinancingAnalyst points out the anticipated $28 million cash burn could strain liquidity and necessitate additional financing, raising dilution and execution risks if capital markets are unfavorable.
Trial Enrollment RiskAnalyst warns that slow enrollment in the pivotal Phase 2 trial could delay key readouts and push back regulatory timelines, increasing development uncertainty.
Cellectis SA News
CLLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $1.10 and its highest was $5.48 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $267.40M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Mar 11, 2026 which is in 28 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Nov 07, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.232 by $0.242.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Undervalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.3.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.232. Following the earnings report the stock price went up 11.285%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in CLLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cellectis SA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (74.73% Upside)
$6.50 (74.73% Upside)
Blogger Sentiment
Bullish
CLLS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.13%
12-Months-Change
Fundamentals
Return on Equity
-31.07%
Trailing 12-Months
Asset Growth
-13.35%
Trailing 12-Months
Company Description
Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
CLLS Stock 12 Month Forecast
Average Price Target
$6.50
▲(74.73% Upside)
Technical Analysis
Cartesian Therapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Zura Bio
―
Ownership Overview
―
Insiders
0.63% Mutual Funds
10.91% Other Institutional Investors
87.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---